Nama's AI scorecard currently rates Zymeworks Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ZYME report earnings?

Zymeworks's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $2.19.

What is the ZYME price target?

The median analyst price target from 14 analysts is $38.50, with a range of $32.00 – $60.00.

Is ZYME Shariah compliant?

Nama's AAOIFI-style screen reads Zymeworks as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Zymeworks (ZYME)

Healthcare · Biotechnology · NASDAQ

Zymeworks (ZYME) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.13B and a free-cash-flow yield of -1.6%. Over the most recent reported fiscal year, revenue grew 38.9%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.5/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +48.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-5.9%

How far the last close sits under the highest price of the past five years.

Market cap	$2.13B
Trailing P/E	—
Price / book	26.5
Price / sales	57.0
FCF yield	-1.6%
Dividend yield	—
Gross margin	-246.7%
Operating margin	-919.0%
Net margin	0.0%
Revenue growth (YoY)	+38.9%
Revenue growth (3-yr annual)	-36.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ZYME earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $2.19). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 6, 2026	-$0.62	-$0.59	-5.1%	$4.59M
Q1 2026	May 7, 2026	-$0.59	-$0.10	-490.0%	$2.41M
Q4 2025	Mar 2, 2026	-$0.55	-$0.32	-71.9%	$2.52M
Q3 2025	Nov 6, 2025	-$0.26	-$0.32	+18.8%	$27.61M

ZYME analyst price target

Median target $38.50 from 14 analysts, ranging $32.00 – $60.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ZYME data on Nama Insights →

ZYME FAQ

Is ZYME a buy?: Nama's AI scorecard currently rates Zymeworks Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ZYME report earnings?: Zymeworks's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $2.19.
What is the ZYME price target?: The median analyst price target from 14 analysts is $38.50, with a range of $32.00 – $60.00.
Is ZYME Shariah compliant?: Nama's AAOIFI-style screen reads Zymeworks as Not Shariah Compliant. At least one of the three ratios or the industry test failed.